C difficile risk
Oral Bioavailability


1 g IV q24h

Note: Should only be used in outpatients. May be considered for inpatient use on day of discharge or for IM administration until IV established for use of other carbepenem.

0 - 30 eGFR30+ eGFR500 mg IV q24h1 g IV q24h

General Information

Targeted therapy of ESBL infections and other resistant gram negative infections

Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity


  • No published human data.

  • No teratogenicity was observed in animal studies.

  • There is no evidence that any beta-lactam antibiotic causes developmental toxicity in humans at therapeutic doses, therefore, if ertapenem is required by the mother, benefit outweighs the unknown risks.


  • Compatible.

  • Immediate and delayed-type allergy

  • GI disturbance

  • Cytopenias, eosinophilia, positive Coombs

  • Liver enzyme abnormalities

  • Seizure risk lower than other carbapenems

Antimicrobial class: Carbapenem

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.